Primary hepatic malignant fibrous histiocytoma combined with invasion of inferior vena cava
A case report and literature review

Yifan Tong, MMa, Hong Yu, MDa, Bo Shen, MDa, Xu Feng, PhDa, Guanglian Wang, MMb, Xiujun Cai, MD, FACS, FRCSa.*

Department of General Surgery, Sir Run Run Shaw Hospital Affiliated to Zhejiang University, Hangzhou, China.

Correspondence: Xiujun Cai, Department of General Surgery, Sir Run Run Shaw Hospital Affiliated to Zhejiang University, Hangzhou 310016, China (e-mail: caixiujunzju@163.com).

Abstract

Rationale: Malignant fibrous histiocytoma (MFH), primary presented in liver, was very rare and displayed a poor prognosis because of high aggression. As a few cases had been reported merely, we shared the case of primary hepatic MFH combined with invasion of inferior vena cava (IVC).

Patients concerns: A 69-year-old women presented with abdominal pain.

Diagnoses: Abdominal computed tomography and magnetic resonance imaging indicated a soft mass about 5.4 × 4.2 cm in the caudate lobe, accompanied with IVC invaded.

Interventions: After the multidisciplinary consultation, laparotomy was performed, followed by chemotherapy and radiotherapy. Primary hepatic MFH was demonstrated pathologically.

Outcomes: Till now, the patient was alive for >22 months after surgery and no evidence of recurrence or distant metastasis was suspected.

Lessons: We discussed the integrated procedure of diagnosis and treatment, combined with data from literature review.

Abbreviations: CT = computed tomography, IVC = inferior vena cava, MFH = malignant fibrous histiocytoma.

Keywords: case report, inferior vena cava, malignant fibrous histiocytoma, pathology

1. Introduction

The malignant fibrous histiocytoma (MFH), an ordinary soft tissue sarcoma, was first described by O’Brien and Stout in 1964,[1,2] which presented in extremities frequently, less commonly in posterior peritoneum.[3,4] Till now, only a handful of these case reports could be recorded through the relative literature.[5–7] Furthermore, no successful comprehensive treatment of primary hepatic MFH combined invasion of inferior vena cava (IVC) was reported, except the case of primary hepatic MFH combined invasion of IVC but dead of pulmonary embolism, was published by Schweyer et al.[8]

Therefore, we shared a case of comprehensive treatment for primary hepatic MFH with invasion of IVC, with a terrific disease-free and overall survival.

2. Case presentation

A 69-year-old women was admitted to our hospital as having recurrent upper abdominal pain for about half a year, aggravated for a week. The patient denied fever, cough, vomiting, or diarrhea in recent period. In terms of previous history, the hypertension was stabilized at 140 mmHg more or less by daily taking oral medicines for 15 years. Besides, well-controlled Hepatitis B for >10 years with regular antiviral therapy was acknowledged. However, the level of blood glucose was indistinct since the diabetes was diagnosed last year.

On physical examination, general condition of patient was well-preserved. The vital signs were stable, and the lung auscultation revealed no rales. Except a slight tenderness in epigastrium and bilateral lower limbs edema, there was no other significant finding.

Laboratory tests showed the white blood cell count of 8.1 × 10⁹ cells/L, the hemoglobin of 111 g/L, and the platelets count of 145 × 10⁹ cells/L. Liver function indicated mildly elevated alanine aminotransferase (58 U/L) and gamma glutamyl transpeptidase (93 U/L), whereas a depressive albumin of 34.8 g/L. Viral serology revealed that HBsAg was positive, corresponding to the history of...
hepatitis B infection. Tumor makers including carcinoembryonic antigen, carbohydrate antigen 19-9, and alpha fetal protein were negative. Arterial blood gases showed no signs of anoxia or acidosis.

Furthermore, abdominal ultrasound indicated a mass adjacent to the second porta hepatis of the liver. An enhanced computed tomography (CT) revealed a hypodense mass (5.4 cm x 4.2 cm, CT values from 5 to 35 HU) in the caudate lobe, accompanied with IVC invaded, and cholecystolithiasis. Enhanced magnetic resonance imaging demonstrated similar results that soft mass presented rapid intensification and attenuation, “Space Occupying Effect”, and cancerous embolism of IVC formed (Fig. 1). However, the heart was tumor-free on echocardiography. Moreover, chest x-ray and CT pulmonary angiography showed no positive signs, although the electrocardiogram revealed sinus rhythm and atrioventricular conduction delay.

After multidisciplinary consultation, the patient diagnosed as having hepatocellular carcinoma initially underwent laparotomy by surgical team (see supplement figure 1, http://links.lww.com/MD/B732). In operation, cancerous thrombus was monitored by the esophagus cardiac ultrasound. Meanwhile, we confirmed the tumor was restricted in the left caudate lobe, closed with the IVC but with tumor-free of atrium dextrum. Therefore, the transabdominothoracic left caudate lobe resection, holecystectomy, and embolectomy of IVC were preformed ultimately. First of all, dissociating the entire liver followed by exposing the caudate lobe as possible as we could. Then cardiac surgeon exposed the hepatic superior IVC with thoracotomy procedure. Eventually, transiently blocking the IVC, removing the tumor and cancerous thrombus integrally, and suturing the IVC rapidly. Afterwards, the patent recovered smoothly, and discharged at 30th day after the operation.

Grossly, the specimen measuring 7.2 cm x 4.0 cm x 2.5 cm presented a gray-to-white fleshy mass about 4.0 cm x 2.0 cm x 2.3 cm filled with necrotic debris and blood clots (Fig. 2). Pathologically, the primary hepatic MFH was confirmed. Microscopically, the tumor...
was consisted of spindle cells arranged in a storiform pattern and contained various amounts of polymorphic cells. In addition, incomplete fibrous intervals were observed mixed with necrotic and hemorrhagic area around the tumor (Fig. 3). Immunohistochemically, CD-68 (Fig. 4) and α1-antichymotrypsin (Fig. 5) were positive, whereas CK, calretinin, CD-117, CD-99, CD-34, SMA, S-100, and Desmin were negative.

A month later, the patient started to receive the chemotherapy as an adjuvant therapy in local hospital. The formula was the ifosfamide 3.0g from 1st day to the 5th day plus liposomal doxorubicin 60mg in the 1st day initially. Subsequently, the patient received a lower dose of following 5 periods of chemotherapy (ifosfamide 3.0g from 1st day to the 4th day plus liposomal doxorubicin 40mg in the 1st day) because of the severe bone marrow inhibition reaction with grade 4, but rapidly recovered with treatment of granulocyte-macrophage colony-stimulating factors. Additionally, a targeted radiotherapy (Experimentally, 10MV–X SAD100/DT200cGy/1F 1st, DT600cGy/3F 5th, DT1600cGy/8F 12th, DT2600cGy/13F 19th, DT3600cGy/18F 26th, DT4600cGy/23F 34th,) around the invaded IVC was performed prophylactically without adverse effect.

Follow-up was carried on every 3 months. The physical examination, serum tumor markers, and abdominal enhanced CT were performed routinely. Till the November 2016 (see supplement Figure 2, http://links.lww.com/MD/B732), the patient was still alive over 22 months, even the recent abdominal enhanced CT showed no evidence of recurrence or metastasis (Fig. 6).

2.1. Literature review

A search of the database Pubmed, according to the “Histiocytoma, Malignant Fibrous”[Mesh], and (“liver” or “hepatic” or “hepato”), was performed. While unrelated to hepatic HMF, or published not in English, were excluded. Full-text articles, including case reports, literature review, letters, editorials, as well as opinion articles, were assessed for eligibility. Reference lists of relevant articles were reviewed and duplicates or information uncomplete cases were removed.

Totally, 40 related literatures were searched, while published not in English (6), abstract only (3), unrelated to hepatic MFH (20), or information (overall survival time) uncomplete cases (1) were excluded. Ten literatures were eligible,[3,6,9–16] which contained 41 cases of hepatic MFH with overall survival (Table 1). Among the 41 cases confirmed pathologically, there were 23 males and 18 females. Generally, the 1-, 3-, and 5-year overall survival rates were 51.9%, 25.6%, and 16.2%, respectively.

3. Discussions

Theoretically, the diagnosis of MFH depends on an accurate differential diagnosis from other sarcomas, which expresses specific surface molecules such as vimentin, CD-68, and α1-antichymotrypsin.[4,9–10] However, the histopathologic concept of MFH including storiform-pleomorphic, myxoid, inflammatory, giant cell, and angiomatoid variants had been eliminated; concomitantly World Health Organization denominated most of the MFH as undifferentiated pleomorphic sarcomas in 2002.[17]

The typical clinical manifestation of primary hepatic MFH contained abdominal pain, jaundice, fever, malnutrition, or asymptomatic.[4,6,11,18,19] Literature review illustrated that hepatic MFH was lack of classical tumor makers and imaging.
Figure 6. In November 2016, the patient received enhanced computed tomography scan, which showed no evidence of recurrence or metastasis.

| Published date/Author | Article types | No. of cases | Age/sex | Tumor location | Overall survival |
|-----------------------|---------------|--------------|---------|----------------|-----------------|
| 1985/Alberti-Flor et al | Case report | 1 | 59/M | Left and right lobe | 14 days |
| 1985/Conran et al | Case report | 1 | 61/M | Left and right lobe | 12 days |
| 1986/Fukuyama et al | Case report | 1 | 38/F | Left lobe | 4 years |
| 1987/Reeves et al | Case report | 1 | 70/F | Left and right lobe | 6 days |
| 1988/Bruneton et al | Case report | 2 | 52/F | Right lobe | 2 years |
| 1988/Honda et al | Case report | 1 | 71/F | Right lobe | 6 months |
| 1990/Kabat et al | Case report | 1 | 61/M | Right lobe | 10 years |
| 1990/Gois et al | Case report | 1 | 70/M | Left and right lobe | 3 months |
| 1991/Chen et al | Case report | 1 | 53/M | Left lobe | 9 years |
| 1991/Fujita et al | Case report | 1 | 62/F | Right lobe | 3 years |
| 1992/Bruneton et al | Case report | 1 | 50/F | Left and right lobe | 6 months |
| 1992/Hamasaki et al | Case report | 1 | 35/F | Left lobe | 10 months |
| 1992/McGrady et al | Case report | 1 | 53/M | Right lobe | 4 years |
| 1993/Zornig et al | Case report | 1 | 54/M | Liver | 6 months |
| 1993/Reed et al | Case report | 1 | 70/M | Left lobe | 4 years |
| 1994/Honda et al | Case report | 1 | 50/M | Right lobe | 3 years |
| 1994/Fujita et al | Case report | 1 | 70/M | Left and right lobe | 4 months |
| 2001/Che et al | Case report | 1 | 70/M | Right lobe | 1 year |
| 2002/Ou et al | Case series and literature review | 1 | 44/F | Liver and lung | 4 months |
| 2002/Yen et al | Case report | 1 | 70/M | Right lobe | 3 months |
| 2002/Yi et al | Case report | 1 | 54/M | Liver | 1 year |
| 2003/Che et al | Case report | 1 | 70/M | Right lobe | 4 years |
| 2004/Yamashita et al | Case report | 1 | 60/F | Right lobe | 8 months |
| 2004/Chen et al | Case report | 1 | 60/F | Right lobe | 5 years |
| 2005/Hamasaki et al | Case report | 1 | 60/F | Pancreas, liver, and lung | 3 years |
| 2006/Sugiyama et al | Case report | 1 | 60/F | Right lobe | 6 months |
| 2006/Chen et al | Case report | 1 | 60/F | Liver and lung | 3 months |
| 2007/Chen et al | Case report | 1 | 54/F | Liver | 1 year |
| 2008/Yamashita et al | Case report | 1 | 70/F | Right lobe | 4 years |
| 2009/Kim et al | Case report | 1 | 60/M | Right lobe | 3 months |
| 2010/Cabral et al | Case report | 1 | 60/F | Pancreas, liver, and lung | 3 months |
| 2010/Jin et al | Case report | 1 | 45/M | Right lobe | 6 months |
| 2012/Yan et al | Case report and literature review | 1 | 56/M | Right lobe | 15 months |
| 2012/Lin et al | Case series | 7 | 44/F (M/F) | Liver | 4 years |

Age is presented as mean in case series; data are presented as survival time and only alive are shown in overall survival. d = days, mo = months, y = years.
presentation clinically.\textsuperscript{19,20} In terms of treatment, surgical resection with negative margin remained the optimal choice,\textsuperscript{13,8} although the median survival without distant metastasis was 8.5 months.\textsuperscript{21} While, either chemotherapy or radiotherapy, as an adjuvant therapy, was benefit of local recurrence but not prolong overall survival, or was preferred for the patient with distant metastasis.\textsuperscript{8,22–23}

In the present case, the chief complaints were abdominal pain and chest distress. Radiology work-ups merely manifested a soft mass near to the second hilum and invasion of IVC, but were unable to identify the MFH from hepatocellular carcinoma or other malignancies, corresponding with literature published.\textsuperscript{3,11}

According to the immunohistochemical results, sarcomatoid carcinoma (CK-negative), malignant mesothelioma (Calretinin-negative), gastrointestinal stromal tumor (CD-117-, CD-99-negative), angiosarcoma (CD-34-negative), leiomyosarcoma (Desmin-negative), malignant peripheral nerve sheath tumor and melanoma (S-100-negative), and rhabdomyosarcoma (SMA-negative) were ruled out. Meanwhile, CD-68, KP-1, and melanoma (S-100-negative), gastrointestinal stromal tumor (CD-117-, CD-99-negative), and CD-1a immunohistochemical results confirmed the diagnosis of MFH.\textsuperscript{1,2} Thus, MFH with margin negative was confirmed pathologically.

Besides the radical resection, chemotherapy and targeted radiotherapy, as adjuvant treatments, were carried out. Till now, the patient was alive for 22 months and no evidence of recurrence or distant metastasis was suspected clinically.

4. Conclusions

In conclusion, primary hepatic MFH possessed a high aggressive behavior and poor prognosis. However, the comprehensive treatment integrating the surgery, chemotherapy, and radiotherapy displayed a terrific short-term result, and presented the potential to improve the disease-free and overall survival. Further investigations are warranted, definitely.

Acknowledgment

The authors appreciate Prof. Mei Jin, the chief of Department of Pathology of Sir Run Run Shaw Hospital, for illustrating pathological results.

References

[1] O’Brien JE, Stout AP. Malignant fibrous xanthomas. Cancer 1964;17:1445–55.
[2] Weiss SW, Enzinger FM. Malignant fibrous histiocytoma: an analysis of 200 cases. Cancer 1978;41:2250–66.
[3] Yao D, Dai C. Clinical characteristics of the primary hepatic malignant fibrous histiocytoma in China: case report and review of the literature. World J Surg Oncol 2012;10:2.
[4] Fu DL, Yang F, Maskay A, et al. Primary intestinal, malignant fibrous histiocytoma: two case reports. World J Gastroenterol 2007;13:1299–302.
[5] Kranzrod MJ. Malignant soft-tissue tumors in a large referral population: distribution of diagnoses by age, sex, and location. Am J Roentgenol 1995;164:129–34.
[6] Su HW, Hsu CS, Lin YH, et al. Malignant fibrous histiocytoma during pregnancy: a case report. Taiwan J Obstet Gynecol 2006;45:86–8.
[7] Lehnhardt M, Daigeler A, Homann HH, et al. MFH revisited: outcome after surgical treatment of undifferentiated pleomorphic or not otherwise specified (NOS) sarcomas of the extremities—an analysis of 140 patients. Langenbecks Arch Surg 2009;394:313–20.
[8] Schweyer S, Meyer-Venter R, Lort T, et al. Malignant fibrous histiocytoma of the liver. Z Gastroenterol 2000;38:243–4.
[9] Kim HS, Kim GY, Lim SJ, et al. Undifferentiated pleomorphic sarcoma of the liver presenting as a unilocular cyst. Hepatobiliary Pancreat Dis Int 2009;8:541–3.
[10] Li YB, Akbari E, Trettakova MS, et al. Primary hepatic malignant fibrous histiocytoma: clinicopathologic characteristics and prognostic value of Erzin expression. Am J Surg Pathol 2008;32:1144–58.
[11] Chen HC, Chen CJ, Jeng CM, et al. Malignant fibrous histiocytoma presenting as hemoperitoneum mimicking hepatocellular carcinoma rupture. World J Gastroenterol 2007;13:6441–3.
[12] Caldeira A, Martin-Carreras F, Pereira E, et al. Malignant fibrous histiocytoma—a rare hepatic tumor. Rev Esp Enferm Dig 2010;102:146–7.
[13] Ye MF, Zheng S, Xu JH, et al. Primary hepatic malignant fibrous histiocytoma: a case report and review of the literature. Histol Histopathol 2007;22:1337–42.
[14] Ding GH, Wu MC, Yang JH, et al. Primary hepatic malignant fibrous histiocytoma mimicking cystadenocarcinoma: a case report. Hepatobiliary Pancreat Dis Int 2006;5:620–3.
[15] Jarry J, Belleuanee G, Laurent C, et al. Primary malignant fibrous histiocytoma of the pancreas: benefit of the multidisciplinary approach. Eur J Gastroenterol Hepatol 2010;22:765–8.
[16] Tan Y, Xiao EH. Rare hepatic malignant tumors: dynamic CT, MRI, and clinicopathologic features with analysis of 54 cases and review of the literature. Abdom Imaging 2013;38:311–26.
[17] Matushansky I, Charytonowicz E, Mills J, et al. MFH classification: differentiating undifferentiated pleomorphic sarcoma in the 21st century. Expert Rev Anticancer Ther 2009;9:1135–44.
[18] Nurdjanah S, Bayupurnama P, Maduseno S, et al. Abdominal malignant fibrous histiocytoma infiltrating stomach with Chilaiditi's sign manifestation (a rare case report). Kobe J Med Sci 2007;53:119–24.
[19] Yu RS, Wang JW, Chen Y, et al. A case of primary malignant fibrous histiocytoma of the pancreas: CT and MRI findings. World J Gastroenterol 2008;14:2942–5.
[20] Cong Z, Gong J, Abdou, et al. Primary malignant fibrous histiocytoma of the liver: CT findings in five histopathological proven patients. Abdom Imaging 2011;36:552–6.
[21] Yin L, Lai CH, Li AJ, et al. Primary hepatic malignant fibrous histiocytoma: diagnostic pitfalls and therapeutic challenge. Hepatogastroenterology 2011;58:887–91.
[22] Beikle E, Ruf I, Budach W, et al. Tandem high-dose chemotherapy supported by autologous peripheral blood stem-cell transplantation and radiotherapy for recurrent malignant fibrous histiocytoma. Wien Klin Wochenschr 2005;117:833–6.
[23] Mandal S, Mandal AK. Malignant fi brous histiocytoma following radiation therapy and chemotherapy for Hodgkin's lymphoma. Int J Clin Oncol 2007;12:32–5.
[24] Tuan J, Vitolo V, Vischinon B, et al. Radiation therapy for retroperitoneal sarcoma, Radiol Med 2014;119:790–802.
[25] Ågoston P, Jorgo K, Mátrai Z. Role of radiotherapy in the treatment of retroperitoneal soft tissue sarcomas. Magy Onkol 2014;58:77–82.